Lars Petter Jordheim Selected Research

5'-Nucleotidase (5' Nucleotidase)

10/2021	Transcriptional and Metabolic Investigation in 5'-Nucleotidase Deficient Cancer Cell Lines.
6/2021	Cytosolic 5'-Nucleotidase II Silencing in Lung Tumor Cells Regulates Metabolism through Activation of the p53/AMPK Signaling Pathway.
12/2018	Expanding the clinical relevance of the 5'-nucleotidase cN-II/NT5C2.
7/2018	Cytosolic 5'-Nucleotidase II Silencing in a Human Lung Carcinoma Cell Line Opposes Cancer Phenotype with a Concomitant Increase in p53 Phosphorylation.
3/2018	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.
9/2017	The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells.
12/2016	Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II.
7/2015	Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models.
4/2014	Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Petter Jordheim Research Topics

Disease

43	Neoplasms (Cancer) 01/2022 - 08/2004
5	Carcinoma (Carcinomatosis) 06/2021 - 01/2015
5	Breast Neoplasms (Breast Cancer) 02/2021 - 07/2011
4	Adenocarcinoma 01/2020 - 08/2005
3	Lung Neoplasms (Lung Cancer) 02/2021 - 01/2021
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 07/2011
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 07/2011
2	Gout 01/2022 - 01/2020
2	Hypercalcemia (Milk Alkali Syndrome) 10/2018 - 04/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2018 - 07/2011
2	Leukemia 12/2016 - 04/2014
1	Melanoma (Melanoma, Malignant) 01/2022
1	Uveal melanoma 01/2022
1	Astrocytoma (Pilocytic Astrocytoma) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Schizophrenia (Dementia Praecox) 12/2018
1	Hereditary Spastic Paraplegia 12/2018
1	Colonic Neoplasms (Colon Cancer) 01/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2017
1	Lymphoma (Lymphomas) 09/2017
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 05/2017
1	Complementation Group F Xeroderma Pigmentosum 10/2014
1	Genomic Instability 10/2014
1	Xeroderma Pigmentosum (Kaposi's Disease) 10/2014
1	Multiple Myeloma 07/2013
1	Virus Diseases (Viral Diseases) 06/2013

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2012
10	NucleosidesIBA 12/2016 - 08/2004
9	EnzymesIBA 01/2022 - 01/2013
9	5'-Nucleotidase (5' Nucleotidase)IBA 10/2021 - 04/2014
8	Gemcitabine FDA Link 01/2020 - 08/2005
6	Biological ProductsIBA 02/2021 - 02/2013
6	NucleotidesIBA 02/2021 - 06/2013
5	Pharmaceutical PreparationsIBA 01/2021 - 01/2013
3	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 01/2020
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2021 - 10/2014
3	PlatinumIBA 03/2018 - 10/2014
3	fludarabineIBA 09/2017 - 02/2013
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 12/2016
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 06/2021
2	Alkylating AgentsIBA 01/2021 - 07/2013
2	Deoxyglucose (2 Deoxy D glucose)IBA 01/2021 - 07/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2011
2	Purine NucleosidesIBA 04/2019 - 05/2017
2	Calcitriol (Calcijex)FDA LinkGeneric 10/2018 - 04/2013
2	Antineoplastic Agents (Antineoplastics)IBA 10/2018 - 04/2013
2	Biomarkers (Surrogate Marker)IBA 03/2018 - 08/2013
2	Clofarabine (Clolar)FDA Link 05/2017 - 02/2013
2	2'-deoxyadenosineIBA 05/2017 - 11/2009
2	Cladribine FDA LinkGeneric 05/2017 - 02/2013
2	Cytotoxins (Cytolysins)IBA 07/2015 - 01/2013
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 07/2011 - 08/2005
2	Phosphotransferases (Kinase)IBA 11/2009 - 10/2006
1	benzamideIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Dinoprostone (PGE2)FDA Link 02/2021
1	Adenosine Monophosphate (AMP)IBA 02/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Deoxyribonuclease I (Nickase)IBA 01/2021
1	Dithiothreitol (Cleland's Reagent)IBA 01/2021
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Caspase 1 (ICE Protease)IBA 01/2021
1	CalciumIBA 11/2020
1	Calcium Channels (Calcium Channel)IBA 11/2020
1	pyrimidineIBA 01/2020
1	Cytidine DeaminaseIBA 01/2020
1	purineIBA 01/2020
1	Pentamidine (NebuPent)FDA LinkGeneric 09/2019
1	Peptides (Polypeptides)IBA 04/2019
1	NanocapsulesIBA 10/2018
1	Drug CarriersIBA 10/2018
1	Recombinant ProteinsIBA 09/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 09/2017
1	Small Interfering RNA (siRNA)IBA 09/2017
1	cladribine triphosphateIBA 05/2017
1	triphosphoric acid (triphosphate)IBA 05/2017
1	Histones (Histone)IBA 10/2014
1	Insulin-Like Growth Factor I (IGF-1)IBA 07/2013
1	Insulin-Like PeptidesIBA 07/2013
1	Bortezomib (Velcade)FDA Link 07/2013
1	DNA Repair EnzymesIBA 07/2013
1	Proteasome InhibitorsIBA 07/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2013
1	Cholecalciferol (Vitamin D3)FDA Link 04/2013
1	AS602868IBA 07/2011

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 03/2018 - 09/2012
3	Therapeutics 01/2022 - 09/2012
2	Ligation 01/2021 - 01/2015
1	Replantation 01/2022
1	Immunotherapy 11/2020
1	Combination Drug Therapy (Combination Chemotherapy) 03/2018
1	Lasers (Laser) 03/2018
1	Aftercare (After-Treatment) 01/2018